XML 56 R35.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies - Additional Information (Details) - USD ($)
 1 Months Ended 12 Months Ended
Dec. 31, 2019
May 31, 2018
Apr. 30, 2018
Dec. 31, 2020
Dec. 31, 2019
Loss Contingencies [Line Items]          
Lessee, operating lease, description The lease term is for 24 months, expiring in January 2022 The lease term expires in April 2021 and the Company has an option to renew for an additional 12 months.      
Operating lease, payments   $ 4,000   $ 17,500  
Lessee, operating lease term of contract 24 months 12 months     24 months
Operating leases, rent expense       $ 273,000 $ 159,000
Teva Agreements          
Loss Contingencies [Line Items]          
Nonrefundable upfront payment     $ 6,000,000    
Payment upon achievement of certain clinical and commercial milestones     135,000,000    
Asset transfer and license agreement, termination period after written notice       120 days  
Asset transfer and license agreement, termination period notice of breach       60 days  
Asset transfer and license agreement termination notice period if bankruptcy petition filed       60 days  
Teva Agreements | Research and Development Expenses          
Loss Contingencies [Line Items]          
Up-front license payment       $ 0 0
Teva Agreements | Teva?s GlycoPEGylated FGF21 Program          
Loss Contingencies [Line Items]          
Payment upon achievement of certain clinical and commercial milestones     67,500,000    
Teva Agreements | Teva?s Development Program          
Loss Contingencies [Line Items]          
Payment upon achievement of certain clinical and commercial milestones     $ 67,500,000    
Restricted Cash And Other Assets Member          
Loss Contingencies [Line Items]          
Security deposit $ 95,000     $ 95,000 $ 95,000